Form 4: Regulus Therapeutics Inc. Executive Acquires Stock Options

Christopher Ray Aker, Sr. VP & General Counsel of Regulus Therapeutics Inc., acquired stock options for 363,000 shares on May 20, 2024.

Summary

• On May 20, 2024, Christopher Ray Aker, the Sr. VP & General Counsel of Regulus Therapeutics Inc., acquired stock options for 363,000 shares.
• The exercise price of these options is $2.01 per share.
• The options vest ratably on a monthly basis over a 48-month period, contingent upon Aker's continuous service to Regulus.
• The options expire on May 19, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grant itself doesn't indicate positive or negative performance, but rather aligns executive incentives.

Positives

• The acquisition of stock options by a high-ranking executive could signal confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 48 months is typical for such grants, aligning with industry norms for incentivizing long-term commitment.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its relative value.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, incentivizing value creation.

Key Dates